XML 21 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenues      
Product sales, net $ 124,901 $ 17,327  
Collaborative revenue   4 $ 61
Total revenues 124,901 [1] 17,331 [1] 61
Operating expenses      
Cost of product sales 9,077 3,075  
License fees and royalties 3,983 1,331 2,500
Research and development 149,189 99,284 73,869
Selling, general and administrative 255,062 186,456 88,304
Total operating expenses 417,311 290,146 164,673
Loss from operations (292,410) (272,815) (164,612)
Interest income, net 4,126 2,763 499
Loss before income taxes (288,284) (270,052) (164,113)
Income tax expense 1,119 1,341 330
Net loss $ (289,403) $ (271,393) $ (164,443)
Net loss per common share, basic and diluted $ (2.36) [2] $ (2.34) [2] $ (1.63)
Weighted average common shares outstanding, basic and diluted 122,600 115,858 100,630
[1] The Company commenced commercial sales of NUPLAZID in May 2016. The quarters after March 31, 2016 reflect net product revenue related to NUPLAZID.
[2] Net loss per common share, basic and diluted, are computed independently for each quarter and the full year based upon respective average shares outstanding. Therefore, the sum of the quarterly net loss per common share amounts may not equal the annual amounts reported.